What is Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share price return in the past 10 years?

Jagsonpal Pharmaceuticals Ltd share price has appreciated 30% annually (CAGR) over the past ten years.

What is the share price of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)?

Company share prices are keep on changing according to the market conditions. The current trading price of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) on 02-Jul-2026 16:59:59 at 16:59 is 235.20.

What is the P/E ratio of Jagsonpal Pharmaceuticals?

The latest standalone P/E ratio of Jagsonpal Pharmaceuticals as of 02-Jul-2026 is 35.94.

What is the P/B ratio of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)?

The latest standalone P/B ratio of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) as of 02-Jul-2026 is 6.52.

What is the 52-week high and low of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)?

The 52-week high of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is Rs. 301.80 and the 52-week low is Rs. 154.90.

Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)
Brand: Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 507789 NSE: JAGSNPHARM Pharmaceuticals & Drugs | Small Cap | Jagsonpal Pharma Share Price

Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 507789 NSE: JAGSNPHARM Pharmaceuticals & Drugs | Small Cap | Jagsonpal Pharma Share Price

Key Metrics

Valuation Multiples

Market Cap

₹1,548 Cr.

Current Price

₹235.2

52-Week Low / High

₹155 / 302

TTM EPS

₹6.5

TTM Sales

₹287 Cr.

Book Value per Share

₹36.1

P/E Ratio

35.94

In line with its 5-year historical median

Industry PE

49.2

Price to Book (P/B)

6.52

Higher than its 5-year historical median

Price to Sales (P/S)

5.39

Higher than its 5-year historical median

EV/EBITDA

20.58

Lower than its 5-year historical median

Dividend Yield

1.06%

Profitability Efficiency

Return on Equity (ROE)

28.51%

Outperforms industry median

Return on Capital Employed (ROCE)

33.14%

Outperforms industry median

Return on Assets (ROA)

21.44%

Operating Profit Margin

19%

Net Profit Margin

20.6%

Gross Profit Margin

20.7%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

28.76%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

121.37%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

146.48%

Asset Quality

Promoter Holding

67.89%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹224 Cr.

Equity

₹13.2 Cr.

Face Value

₹2

All Time Low / High

₹0.50 / 328.02

Jagsonpal Pharmaceuticals stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Jagsonpal Pharmaceuticals Ltd a good quality company?

Jagsonpal Pharmaceuticals Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Jagsonpal Pharmaceuticals Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Jagsonpal Pharmaceuticals Ltd vs industry peers?

Jagsonpal Pharmaceuticals Ltd revenue CAGR is 11.13%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Jagsonpal Pharmaceuticals Ltd?

Promoters hold 67.89% of the Jagsonpal Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Jagsonpal Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 31.6% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	7.3%	14.3%	-10.5%	9.8%	9.5%	19.4%	21.2%	24.2%	17.7%	33.1%	-
Value Creation Index ⓘ	-0.5	0.0	-1.8	-0.3	-0.3	0.4	0.5	0.7	0.3	1.4	-
Growth Parameters ⓘ
Sales ⓘ	143	144	127	167	159	188	218	237	209	269	287
Sales YoY Gr.	-	0.3%	-12.1%	31.9%	-5%	18.5%	15.8%	8.8%	-11.8%	28.8%	-
Adj EPS ⓘ	0.5	0.4	-1.8	1.1	1.2	2.6	2.8	4.4	3.4	6.3	6.5
YoY Gr.	-	-12%	-500%	NA	9.1%	116.7%	7.7%	57.1%	-22.7%	84.1%	-
BVPS (₹) ⓘ	13.8	15.6	13.8	14.8	15.8	17.4	20.3	22.9	25.8	32.8	36.1
Adj Net Profit ⓘ	3.3	2.9	-11.6	7.2	7.9	17.1	18.4	28.8	22.5	41.6	43
Cash Flow from Ops. ⓘ	9	-3.2	-1.6	30.9	11.9	28.2	6.9	46.7	35.2	55.3	-
Debt/CF from Ops. ⓘ	4.3	-2.5	-5.3	0.1	0.5	0.2	0	0	0	0	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	7.2%	11.1%	7.3%	28.8%
Adj EPS ⓘ	32.4%	39.2%	30.8%	84.1%
BVPSⓘ	10.1%	15.8%	17.4%	27.4%
Share Price	30%	31%	16.4%	2.4%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	3.4	2.8	-11.1	7.1	7.3	14.6	14.4	19.7	13	19.5	19
Op. Profit Mgn % ⓘ	8.2	4	-8.8	5.6	5.4	10.2	11.7	14.6	11.1	19	20.2
Net Profit Mgn % ⓘ	2.3	2	-9.1	4.3	5	9.1	8.4	12.2	10.8	15.5	15
Debt to Equity ⓘ	0.4	0.1	0.1	0	0.1	0.1	0	0	0	0	0
Working Cap Days ⓘ	227	243	277	178	82	65	102	96	92	77	111
Cash Conv. Cycle ⓘ	180	190	209	110	26	10	26	26	27	20	91

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	143	144	127	167	159	188	218	237	209	269
Operating Expenses ⓘ +	132	138	138	157	150	169	193	203	186	218
Manufacturing Costs	4	3	2	2	1	1	2	1	1	1
Material Costs	59	59	61	73	56	81	89	92	80	96
Employee Cost	38	41	42	47	50	54	58	65	62	71
Other Costs ⓘ	31	35	33	36	42	33	44	44	43	49
Operating Profit ⓘ	12	6	-11	9	9	19	25	34	23	51
Operating Profit Margin (%)	8.2%	4.0%	-8.8%	5.6%	5.4%	10.2%	11.5%	14.4%	11.1%	19.0%
Other Income ⓘ +	1	0	0	1	3	4	3	6	9	8
Exceptional Items ⓘ	0	13	0	0	0	0	0	-3	0	20
Interest ⓘ	5	3	1	1	1	1	0	0	1	1
Depreciation ⓘ	3	2	0	1	1	1	2	1	2	8
Profit Before Tax ⓘ	4	14	-12	9	9	22	27	35	30	70
Tax ⓘ	1	3	-0	2	2	5	8	8	7	14
Profit After Tax	3	12	-12	7	8	17	19	27	22	55
PAT Margin (%)	2.3%	8.3%	-9.1%	4.3%	5.0%	9.1%	8.7%	11.3%	10.8%	20.6%
Adjusted EPS (₹)	0.5	1.8	-1.8	1.1	1.2	2.6	2.9	4.1	3.4	8.3
Dividend Payout Ratio (%)	8.10%	2.20%	-2.30%	9.10%	16.60%	15.40%	55.60%	49%	58.90%	30%

Valuation of Jagsonpal Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	98	110	98	104	111	122	133	150	170	218
Share Capital ⓘ	13	13	13	13	13	13	13	13	13	13
Reserves ⓘ	85	97	85	91	98	109	120	137	157	205
Debt +	38	8	8	4	6	7	0	0	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	38	8	8	4	6	7	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	10	9	9	12	12	18	19	17	8	10
Others Liabilities ⓘ	13	16	14	16	20	17	20	36	47	64
Total Liabilities ⓘ	159	143	130	136	149	164	171	203	225	292
Fixed Assets
Net Fixed Assets ⓘ +	52	22	21	22	24	26	23	24	9	94
Gross Block	90	53	54	55	58	60	58	33	12	103
Accumulated Depreciation	39	31	32	33	34	34	36	9	2	9
CWIP ⓘ	0	0	3	4	2	0	0	0	0	0
Investments ⓘ	0	0	0	0	11	15	51	1	0	0
Inventories	40	48	51	33	29	30	30	21	15	15
Trade Receivables	42	39	25	21	21	13	16	21	11	13
Cash Equivalents ⓘ	16	20	15	39	40	60	25	115	148	129
Others Assets ⓘ	11	14	14	18	20	21	28	21	41	40
Total Assets ⓘ	159	143	130	136	149	164	171	203	225	292

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	9	-3	-2	31	12	28	7	47	35	55
PBT ⓘ	4	14	-12	9	9	22	27	35	30	70
Adjustment ⓘ	8	-9	1	0	-1	-2	-1	10	8	-12
Changes in Working Capital ⓘ	-2	-6	9	20	5	12	-11	9	6	6
Tax Paid ⓘ	-1	-3	0	2	-2	-3	-7	-7	-9	-8
Cash Flow From Investing Activity ⓘ +	-2	41	-3	-1	-11	-2	-26	-58	-25	-45
Capex	-3	41	-4	-2	-2	-0	-0	1	-0	35
Net Investments	0	0	0	0	-11	-4	-27	-62	-32	5
Others ⓘ	1	0	0	1	2	2	2	3	7	-86
Cash Flow From Financing Activity ⓘ +	-6	-34	-1	-6	-2	-7	-18	-0	-9	-12
Net Proceeds from Shares ⓘ	0	0	0	0	0	-4	0	0	6	3
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-5	-3	-1	-1	-1	-1	-0	-0	-1	-1
Dividend Paid ⓘ	-0	-0	-0	-1	-1	-3	-10	0	-13	-13
Others ⓘ	-1	-31	0	-5	0	0	-7	-0	-1	-1
Net Cash Flow ⓘ	1	5	-6	24	-1	19	-36	-11	2	-2

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	3.65	12.32	-12.01	7.72	7.88	15.7	15.28	18.89	14.02	28.51
ROCE (%)	7.32	14.26	-10.52	9.8	9.46	19.43	21.23	24.15	17.72	33.14
Asset Turnover Ratio	0.92	0.96	0.93	1.26	2.23	2.4	1.45	1.38	1.05	1.09
PAT to CFO Conversion(x)	3	-0.25	N/A	4.43	1.5	1.65	0.37	1.74	1.59	1
Working Capital Days
Receivable Days	109.60	102	93.10	50.20	24.30	16.60	21.30	25.90	25.90	15.60
Inventory Days	92.30	110	142.80	92	35.70	28.70	44.80	35.80	29	19.60
Payable Days	43.20	49.20	54	52.50	76.60	67.20	75.10	69.40	55.20	32.80

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Jagsonpal Pharmaceuticals Ltd FAQs

The current trading price of Jagsonpal Pharma on 02-Jul-2026 16:59 is ₹235.2.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jul-2026 the market cap of Jagsonpal Pharma stood at ₹1,548.5 Cr

The latest P/E ratio of Jagsonpal Pharma as of 01-Jul-2026 is 35.94.

The latest P/B ratio of Jagsonpal Pharma as of 01-Jul-2026 is 6.52.

The 52-week high of Jagsonpal Pharma is ₹301.8 and the 52-week low is ₹154.9.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Jagsonpal Pharma is ₹287 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Jagsonpal Pharmaceuticals Ltd is a good quality company.

The key valuation ratios of Jagsonpal Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Jagsonpal Pharmaceuticals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Jagsonpal Pharmaceuticals Ltd

In 1964 Jagsonpal started from humble beginnings with Jagmohan S. Kochhar operating a chemists shop in Delhi. Soon he expanded into making formulations. Mr. Kochharâ€™s vision was to spread health and healing in India on a larger scale. He was at the helm of the company from its inception, through the startup phase. Even though Jagsonpal was a small business at the time, his vision was to create one of Indiaâ€™s premiere pharmaceutical companies.

In 1978, Fourteen years later, the company had outgrown the startup phase and was incorporated as a private limited company. Jagsonpal was now a fast growing pharmaceutical company. The firm was committed to healing India with quality pharmaceutical products and had its eyes firmly set on becoming one of the countryâ€™s leading pharmaceutical companies.

In 1986 Jagsonpal went public on the BSE. This was the first time the firm had tapped the capital markets.

In 1994 the company was listed on the NSE. This trait of not being content with the status quo has become a core part of Jagsonpalâ€™s company culture. Commitment to growth is ingrained in the very soul of the company and this is reflected in the Jagsonpalâ€™s current aggressive growth strategy.

Jagsonpal is among Indiaâ€™s premiere pharmaceutical companies. Jagsonpal has substantial research and development, manufacturing, marketing and distribution facilities. An impeccable track record of growth and profitability spanning over 4 decades, makes Jagsonpal an ideal company to partner with. The company specializes in developing and manufacturing bulk drugs and pharmaceutical formulations. The firm is committed to sustainable growth and is aggressively pursuing growth through market penetration, market expansion and multi-national expansion.

The firmâ€™s objective is to increase market share and become a dominant player in the Indian Pharmaceutical Industry.Jagsonpal has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe making it a truly international operation.

Product range of the company includes:

Dextropropoxyphene
Tolnaftate
Indocap SR
Sterile Unipacks
Thiopental sodium

Upcoming products:

Nandralone laurate
Ethisterone
Norgestimate
Estradiol
Estradiol benzoate
Estradiol valerate
Estradiol phenylpropionate
Mifepristone
Finasteride/dutasteride
Budesonide
Cyproterone/acetate
Mestranol
Llynestrenol
Norethisterone enanthate
Estriol base and succinate
Ethinyl estradiol
Estrone

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)

Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)

Jagsonpal Pharmaceuticals stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Jagsonpal Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Jagsonpal Pharmaceuticals Ltd FAQs

What is the share price of Jagsonpal Pharma?

What is the market cap of Jagsonpal Pharma?

What is the P/E ratio of Jagsonpal Pharma?

What is the P/B ratio of Jagsonpal Pharma?

What is the 52-week high and low of Jagsonpal Pharma?

What is the TTM revenue of Jagsonpal Pharma?

Is Jagsonpal Pharmaceuticals Ltd a good quality company?

Is Jagsonpal Pharmaceuticals Ltd undervalued or overvalued?

Is Jagsonpal Pharmaceuticals Ltd a good buy now?

About Jagsonpal Pharmaceuticals Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.